PMID- 23609581
OWN - NLM
STAT- MEDLINE
DCOM- 20140116
LR  - 20240109
IS  - 1660-3397 (Electronic)
IS  - 1660-3397 (Linking)
VI  - 11
IP  - 4
DP  - 2013 Apr 22
TI  - Immunomodulatory effect of marine cembrane-type diterpenoids on dendritic cells.
PG  - 1336-50
LID - 10.3390/md11041336 [doi]
AB  - Dendritic cells (DCs) are antigen presenting cells, which can present antigens to 
      T-cells and play an important role in linking innate and adaptive immunity. DC 
      maturation can be induced by many stimuli, including pro-inflammatory cytokines 
      and bacterial products, such as lipopolysaccharides (LPS). Here, we examined the 
      immunomodulatory effects of marine cembrane compounds, 
      (9E,13E)-5-acetoxy-6-hydroxy-9,13-dimethyl-3- 
      methylene-3,3a,4,5,6,7,8,11,12,14a-decahydro-2H-cyclotrideca[b]furan-2-one (1), 
      (9E,13E)- 
      5-acetoxy-6-acetyl-9,13-dimethyl-3-methylene-3,3a,4,5,6,7,8,11,12,14a-decahydro-2H-cyclotrideca[b]furan-2-one 
      (2), lobocrassin B (3), (-)14-deoxycrassin (4), cembranolide B (5) and 
      13-acetoxysarcocrassolide (6) isolated from a soft coral, Lobophytum crassum, on 
      mouse bone marrow-derived dendritic cells (BMDCs). The results revealed that 
      cembrane-type diterpenoids, especially lobocrassin B, effectively inhibited 
      LPS-induced BMDC activation by inhibiting the production of TNF-alpha. Pre-treatment 
      of BMDCs with Lobocrassin B for 1 h is essential to prohibit the following 
      activation induced by various toll-like receptor (TLR) agonists, such as LPS, 
      zymosan, lipoteichoic acid (LTA) and Pam2CSK4. Inhibition of NF-kappaB nuclear 
      translocation by lobocrassin B, which is a key transcription factor for cytokine 
      production in TLR signaling, was evident as assayed by high-content image 
      analysis. Lobocrassin B attenuated DC maturation and endocytosis as the 
      expression levels of MHC class II and the co-stimulatory molecules were 
      downregulated, which may affect the function of DCs to initiate the T-cell 
      responses. Thus, lobocrassin B may have the potential in treatment of immune 
      dysregulated diseases in the future.
FAU - Lin, Ching-Yen
AU  - Lin CY
AD  - Department of Life Science and Institute of Biotechnology, National Dong Hwa 
      University, Hualien 974, Taiwan. jouyuan22@gmail.com
FAU - Lu, Mei-Chin
AU  - Lu MC
FAU - Su, Jui-Hsin
AU  - Su JH
FAU - Chu, Ching-Liang
AU  - Chu CL
FAU - Shiuan, David
AU  - Shiuan D
FAU - Weng, Ching-Feng
AU  - Weng CF
FAU - Sung, Ping-Jyun
AU  - Sung PJ
FAU - Huang, Kao-Jean
AU  - Huang KJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130422
PL  - Switzerland
TA  - Mar Drugs
JT  - Marine drugs
JID - 101213729
RN  - 0 (Diterpenes)
RN  - 0 (Immunologic Factors)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (Toll-Like Receptors)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (lobocrassin B)
SB  - IM
MH  - Animals
MH  - Anthozoa/*metabolism
MH  - Bone Marrow Cells/immunology/metabolism
MH  - Dendritic Cells/*drug effects/immunology
MH  - Diterpenes/isolation & purification/*pharmacology
MH  - Endocytosis/drug effects
MH  - Immunologic Factors/isolation & purification/*pharmacology
MH  - Lipopolysaccharides/toxicity
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - NF-kappa B/drug effects/metabolism
MH  - T-Lymphocytes/drug effects/immunology
MH  - Time Factors
MH  - Toll-Like Receptors/agonists/metabolism
MH  - Tumor Necrosis Factor-alpha/biosynthesis
PMC - PMC3705408
EDAT- 2013/04/24 06:00
MHDA- 2014/01/17 06:00
PMCR- 2013/04/01
CRDT- 2013/04/24 06:00
PHST- 2013/02/26 00:00 [received]
PHST- 2013/03/22 00:00 [revised]
PHST- 2013/03/27 00:00 [accepted]
PHST- 2013/04/24 06:00 [entrez]
PHST- 2013/04/24 06:00 [pubmed]
PHST- 2014/01/17 06:00 [medline]
PHST- 2013/04/01 00:00 [pmc-release]
AID - md11041336 [pii]
AID - marinedrugs-11-01336 [pii]
AID - 10.3390/md11041336 [doi]
PST - epublish
SO  - Mar Drugs. 2013 Apr 22;11(4):1336-50. doi: 10.3390/md11041336.